Yet To Consolidate
Even after 50,000 angioplasts being
conducted every year in India, the country's indigenous drug eluting
stents (DES) industry is still struggling to consolidate its position
in the market. This is mainly due to lack of adequate support from
established cardiologists, according to a top official of a major
indigenous DES manufacturer.
True Pack To Invest Rs. 8 Cr. For
Advanced Pharma Packaging Plant
True Pack, a dedicated pharmaceutical
packaging major and a leader in the south India, is investing around
Rs 8 crore to set up a state-of-the-art plant close to its present
premises at Peenya Industrial Area in Bangalore. The facility, which
is around 60,000 sq. ft. will conform to class 100/10K standards. The
first phase of construction of 20,000 sq. ft. is expected to be
completed by March 2006.
India's First Indigenous Drug Eluting
Stent Receives CE Approval
Sahajanand Medical Technologies (SMT) has
received CE approval (Conformité Européenne), an authorisation
certificate, for qualification for the sale of Infinnium in European
community and many other countries in the world. The Infinnium
paclitaxel eluting coronary stent system is the first (Asian)
indigenously developed coronary stent for the treatment of coronary
artery disease (CAD) and offers unmatched clinical outcomes with
excellent safety profile.
Hindustan Latex Sets Rs. 1000 Cr.
Turnover Target By 2010
Hindustan Latex Limited (HLL) has drawn up
an ambitious turnover target of Rs 1000 crore by 2010 and to achive
this it has chalked out a comprehensive plan of expanding its
portfolio of health care and contraceptive products. The company has
signed a Memorandum of Understanding with AIMU Medical Science and
Technology Ltd, Anshan, China, for introducing a new generation of
intra uterine devices (IUD).
Pall and Biotrace Sign Global Agreement
to Market Microbiological Air Monitoring Technology to the
Pall Corporation (NYSE: PLL) announced
today that it has entered into an agreement with Biotrace
International Plc (LSE: BOI) giving Pall exclusive global marketing
and distribution rights to the range of Ascotec environmental air
monitoring products for the pharmaceutical industry. As part of the
worldwide agreement, the two companies will also work together on the
development of additional innovative products for the rapid detection
of contamination. Microbiological monitoring of manufacturing
processes is critical to ensuring compliance with regulatory
requirements and product safety.